Latest News about RHHBY
Recent news which mentions RHHBY
Why Adaptimmune Therapeutics Stock Is Bolting Higher Today
September 07, 2021
From Motley Fool
Adaptimmune Stock Moves Higher On Cancer Deal With Genentech
September 07, 2021
From Benzinga
Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy
September 07, 2021
From Benzinga
Is Exelixis Stock a Buy?
September 02, 2021
From Motley Fool
COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?
August 31, 2021
From Motley Fool
From Benzinga
From Benzinga
From Benzinga
Which Biotech Stock Will Shock the Market in 2022?
August 27, 2021
From Motley Fool
Shape Therapeutics, Roche Form $3B RNA Editing Collaboration
August 24, 2021
From Benzinga
Why Shares of Global Blood Therapeutics Are Soaring Today
August 23, 2021
From Motley Fool
UK Approves Regeneron - Roche's COVID-19 Antibody Cocktail
August 20, 2021
From Benzinga
Could Biogen Acquire Axsome Therapeutics?
August 20, 2021
From Motley Fool
From Benzinga
AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer
August 09, 2021
From Benzinga
Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Newly Diagnosed DLBCL Patients
August 09, 2021
From Benzinga
Here Are the Winners of Cowen's Big Pharma R&D Showdown
August 07, 2021
From Motley Fool
These OTC Securities Had the Most Trading Activity in July
August 06, 2021
From Benzinga
From InvestorPlace
From Motley Fool
From Benzinga
From Benzinga
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money
August 04, 2021
From Motley Fool
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
August 03, 2021
From Benzinga
From Benzinga
Roche's Tecentriq As Adjuvant Treatment Under Priority Review With FDA For Early Lung Cancer
August 03, 2021
From Benzinga
FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
August 02, 2021
From Benzinga
From Motley Fool
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
July 29, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.